Plus Therapeutics Stock Jumps After FDA Orphan Drug Win for Kids’ Rare Brain Tumors
Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors.
/ 111 items
#XY Event-Driven Stocks↓
ANI Pharmaceuticals Stock Jumps After FDA OKs New Generic Heart Drug
ANI Pharma shares jump as it launches FDA-approved generic Monoket to prevent chest pain from heart disease.
Oscar Health CEO Buys $11.9 Million of Stock
Oscar Health CEO bought $11.9M in shares after stock payout, showing strong confidence. Shares jumped.
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Misses All Endpoints
Insmed’s HS drug failed to beat placebo in a mid-stage trial, though it was safe. Development for this condition has been stopped.
Gilead’s Third Deal of 2026: $3.15B Buyout of ADC Specialist Tubulis
Gilead buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026.
FDA Gives Fast Track Boost to Climb Bio’s Budoprutug for Primary Membranous Nephropathy
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.